Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

1,800

Employees1,800

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

1,800

Employees1,800

NBIX Key Statistics

Market cap

10.04B

Market cap10.04B

Price-Earnings ratio

30.41

Price-Earnings ratio30.41

Dividend yield

—

Dividend yield—

Average volume

2.17M

Average volume2.17M

High today

$102.05

High today$102.05

Low today

$99.09

Low today$99.09

Open price

$99.35

Open price$99.35

Volume

1.93M

Volume1.93M

52 Week high

$157.98

52 Week high$157.98

52 Week low

$84.23

52 Week low$84.23

NBIX News

Benzinga 3d

Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish

A physician survey for Neurocrine Biosciences Inc's NBIX Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine...

Benzinga 3d

This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

TipRanks 3d

Neurocrine upgraded to Buy from Hold at Needham

Needham analyst Ami Fadia upgraded Neurocrine (NBIX) to Buy from Hold with a $138 price target Published first on TheFly – the ultimate source for real-time, m...

Analyst ratings

81%

of 27 ratings

Buy

81.5%

Hold

18.5%

Sell

More NBIX News

TipRanks 4d

Neurocrine upgraded to Outperform at RBC Capital following pullback

As previously reported, RBC Capital upgraded Neurocrine (NBIX) to Outperform from Sector Perform with a price target of $137, down from $138. Weakness in the sh...